CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome
Authors:
- Helle Al-HakemHAHelle Al-Hakem
- Alex Y. DoetsADAlex Y. Doets
- Amro Maher StinoASAmro Maher Stino
- Sasha A. ZivkovicSZSasha A. Zivkovic
- Henning AndersenHAHenning Andersen
- Hugh J. WillisonHWHugh J. Willison
- David R. CornblathDCDavid R. Cornblath
- Kenneth C. GorsonKGKenneth C. Gorson
- Zhahirul IslamZIZhahirul Islam
- Quazi Deen MohammadQMQuazi Deen Mohammad
- Søren Hein SindrupSSSøren Hein Sindrup
- Susumu KusunokiSKSusumu Kusunoki
- 6 June 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (23) , E2386-E2397
Abstract
To investigate cerebrospinal fluid findings in relation to clinical and electrodiagnostic subtypes, severity, and outcome of Guillain-Barré syndrome based on 1500 patients in the International GBS Outcome Study. Albuminocytological dissociation was defined as an increased protein level (>0.45 g/L) in absence of elevated white cell count (4 days 84%. High CSF protein levels were associated with a demyelinating subtype, proximal or global muscle weakness and a reduced likelihood of being able to run at week 2 (OR: 0.42 (95% CI 0.25-0.70; p = 0.001) and week 4 (OR: 0.44 (95% CI 0.27-0.72; p = 0.001). Patients with the Miller Fisher syndrome, distal predominant weakness and normal or equivocal nerve conduction studies were more likely to have lower CSF protein levels. CSF cell count was <5 cells/µL in 1005 patients (83%), 5-49 cells/µL in 200 patients (16%) and ≥50 cells/µL in 13 patients (1%). Albuminocytological dissociation is a common finding in Guillain-Barré syndrome, but normal protein levels do not exclude this diagnosis. High CSF protein level is associated with an early severe disease course and a demyelinating subtype. Elevated CSF cell count, rarely ≥50 cells/µL, is compatible with GBS after thorough exclusion of alternative diagnoses. This study provides Class IV evidence that CSF albuminocytologic dissociation (defined by the Brighton Collaboration) is common in patients with GBS.Keywords
This publication has 33 references indexed in Scilit:
- Increased cerebrospinal fluid protein and motor conduction studies as prognostic markers of outcome and nerve ultrasound changes in Guillain–Barré syndromeJournal of the Neurological Sciences, 2014
- Diagnosis of Guillain-Barre syndrome and validation of Brighton criteriaBrain, 2013
- Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety dataVaccine, 2011
- Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task forceEuropean Journal of Neurology, 2006
- Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcomeAnnals of Neurology, 1998
- Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain‐Barré syndromeMuscle & Nerve, 1991
- Assessment of current diagnostic criteria for Guillain-Barr syndromeAnnals of Neurology, 1990
- CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHYThe Lancet, 1978
- Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference valuesScandinavian Journal of Clinical and Laboratory Investigation, 1977